Arudchelvam Udhishtran, Pulendran Thayaparan, Sirimanne Maheshi, Pabasara Sandali, Kahawita Indira, Chandraratne Nadeeka
Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Central Leprosy Clinic, National Hospital of Sri Lanka, Colombo, Sri Lanka.
BMC Infect Dis. 2025 Jan 31;25(1):148. doi: 10.1186/s12879-025-10537-x.
Leprosy, being a neglected tropical disease, remains a significant public health concern in several parts of the world, especially Sri Lanka, where it has long been associated with stigma. This study aims to assess the stigma faced by People Affected by Leprosy (PAL) undergoing treatment and to identify the factors associated with this stigma.
A cross-sectional study was conducted among 109 Leprosy affected people attending the Central Leprosy Clinic and all dermatology clinics of the National Hospital of Sri Lanka (Colombo), selected using a consecutive sampling method. Data collection was done through an interviewer-administered questionnaire. Stigma was quantified using a validated and adapted version of the Stigma Assessment and Reduction of Impact (SARI) tool, which evaluates stigma pertaining to four domains: Experienced Stigma (ES), Disclosure Concerns (DC), Internalized Stigma (IS), and Anticipated Stigma (AS). Spearman's correlation and Mann-Whitney U tests were used to analyze associations, with statistical significance set at 0.05.
The dataset showed a non-normal, right-skewed distribution. The mean total SARI score was 9.82 (SD = 10.23). Disclosure Concerns (r=-2.66; p = 0.005) and Anticipated Stigma (r=-3.6; p < 0.001) demonstrated weak - moderate negative correlations with the time since diagnosis. On the other hand, the correlation between time since diagnosis and Experienced Stigma (r=0.22; p = 0.022) was positive and weak. Participants without disability had significantly lower scores in DC (p = 0.049), IS (p = 0.01), and AS (p = 0.01) compared to those with disability. Patients who did not develop Leprosy reactions displayed significantly lower scores across all SARI domains as well as the total SARI score (all p < 0.05) compared to those who did.
The findings suggest that over time, People Affected by Leprosy become less concerned about disclosing their diagnosis and anticipate less stigma but may experience greater overall stigma. Disability status and Leprosy reactions are key factors in determining the level of stigma faced by them.
麻风病作为一种被忽视的热带病,在世界上多个地区,尤其是斯里兰卡,仍然是一个重大的公共卫生问题,长期以来它一直与耻辱感相关联。本研究旨在评估正在接受治疗的麻风病患者(PAL)所面临的耻辱感,并确定与这种耻辱感相关的因素。
采用连续抽样方法,对前往中央麻风病诊所及斯里兰卡国家医院(科伦坡)所有皮肤科诊所就诊的109名麻风病患者进行了横断面研究。通过访员管理的问卷进行数据收集。使用经过验证和改编的耻辱感评估与影响降低(SARI)工具对耻辱感进行量化,该工具评估与四个领域相关的耻辱感:经历的耻辱感(ES)、披露担忧(DC)、内化的耻辱感(IS)和预期的耻辱感(AS)。采用Spearman相关性分析和Mann-Whitney U检验来分析关联,设定统计学显著性水平为0.05。
数据集呈现非正态、右偏态分布。SARI总得分的平均值为9.82(标准差=10.23)。披露担忧(r=-2.66;p=0.005)和预期的耻辱感(r=-3.6;p<0.001)与确诊后的时间呈弱至中度负相关。另一方面,确诊后的时间与经历的耻辱感之间的相关性为正且较弱(r=0.22;p=0.022)。与有残疾的参与者相比,无残疾的参与者在披露担忧(p=0.049)、内化的耻辱感(p=0.01)和预期的耻辱感(p=0.01)方面得分显著更低。与出现麻风病反应的患者相比,未出现麻风病反应的患者在所有SARI领域以及SARI总得分上均显著更低(所有p<0.05)。
研究结果表明,随着时间推移,麻风病患者对披露其诊断的担忧减少,预期的耻辱感降低,但可能会经历更大的总体耻辱感。残疾状况和麻风病反应是决定他们所面临耻辱感程度的关键因素。